Form 4: ATAI Life Sciences Director Acquires Stock Options
SEC Form 4 Filing
Sabrina Martucci Johnson, a director of ATAI Life Sciences N.V., acquired 103,000 stock options on June 13, 2024.
Summary
- On June 13, 2024, Sabrina Martucci Johnson, a director of ATAI Life Sciences N.V., acquired 103,000 stock options.
- The options have an exercise price of $1.34.
- The stock options shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 13, 2025.
- The options expire on June 13, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of transaction: Sabrina Martucci Johnson acquired 103,000 stock options. |
| 06/13/2025 | Stock options vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or this date. |
| 06/13/2034 | Expiration date of the stock options. |
| 06/14/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.